Choosing a dose-finding design
Choose a dose-finding design by the safety target, activity goal, follow-up time and behavior under simulated scenarios.
Fit
When it matters, and when it does not
It matters when
- You need to choose a dose or schedule before a larger efficacy trial.
- You can monitor harm promptly and define rules for escalation, stopping and dose selection.
It matters less when
- You need to model how an outcome varies across measured doses. Consider dose-response regression. Read: Choosing a dose-response analysis
- You have chosen a dose and need to screen its response rate. Consider a single-arm phase II trial.
Before you start
What to check in your study
- The dose-selection goalSpecify toxicity, activity, exposure or their trade-off. The goal depends on the intervention.
- Dose levels, schedules and observation windowsSet starting doses, permitted jumps and when enough follow-up is available to escalate.
- Allocation, stopping and expansion rulesDefine the safety oversight and the complete decision process, including delayed harms and missing outcomes.
- The assumed dose ordering fits the intervention.How to check: Many oncology toxicity models assume harm rises with dose. Activity may plateau, and schedules may not share that ordering.
- Safety decisions account for incomplete follow-up.How to check: A pending toxicity outcome is not absence of toxicity. Use a method designed for delayed events or pause enrollment.
- The complete design has acceptable behavior under plausible scenarios.How to check: Simulate correct dose selection, exposure to unsafe doses and early stopping. Vary the dose-response curve and accrual rate.
Plain language
How it works
Rule-based, Model-based and Model-assisted approaches use different information to guide allocation. Compare their safety constraints, dose-selection target and ability to handle delayed harm. Use the 3+3, continual reassessment and BOIN pages for their procedures. Compare the complete designs through simulation before recruitment.
Escalation explores doses; expansion gathers more data at selected doses. Selection remains uncertain, and expansion alone does not confirm benefit. Toxicity-focused oncology designs often target a maximum tolerated dose. Other treatments may need an optimal biological dose, joint activity and safety goals, or a schedule comparison.
Worked example
A worked example
- Setting
- An invented oncology cohort receives one dose with a prespecified toxicity window.
- Question
- What does the observed toxicity proportion tell you?
- Approach
- Wait for all patients to complete the window. Record 3 dose-limiting toxicities among 12 patients.
- Result
- The observed proportion is 25 in 100, from 3 of 12 patients.
- What it means
- That is a descriptive proportion, not proof that the dose meets the target. Follow the chosen design; do not invent an escalation rule.
In practice
Recent studies PubMed search · not vetted
Watch out
Common mistakes
The one to remember
A dose selected from a small early-phase trial is uncertain. The highest tolerated dose need not give the best benefit-risk balance, and an expansion cohort does not prove efficacy.
- Assuming the familiar 3+3 rule reliably selects the target dose.Instead: Compare its behavior with model-based or model-assisted designs through simulation.
- Treating maximum tolerated dose as the best dose for every therapy.Instead: Oncology toxicity targets do not fit every intervention. Consider activity, exposure, chronic harm and patient burden.
- Using a dose-response regression as a dose-allocation engine.Instead: A fitted curve alone supplies no safety oversight, escalation rule or stopping policy.
Inside Mallard
How Mallard uses this
Plans do not link to this concept yet. Mallard has no sample-size form for dose-finding and early-phase trials. A plan sized by simulation gets no headline sample size; Mallard does not run that simulation.
concept.choosing_dose_finding, the id a plan cue records.Related Learn pages
Related designs and methods
Evidence
Sources & further reading
- Continual reassessment method: a practical design for phase 1 clinical trials in cancer (opens in a new tab) · Biometrics
- Sequential designs for phase I clinical trials with late-onset toxicities (opens in a new tab) · Biometrics · doi 10.1111/j.0006-341x.2000.01177.x
- Dose-finding based on efficacy-toxicity trade-offs (opens in a new tab) · Biometrics · doi 10.1111/j.0006-341X.2004.00218.x
- Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials (opens in a new tab) · Clin Cancer Res · doi 10.1158/1078-0432.CCR-16-0592
- Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance (opens in a new tab) · BMJ · doi 10.1136/bmj-2023-076387